Parecoxib Sodium CAS NO.198470-85-8

1. Superior quality 
2.Competitive price 
3. Good service 
4. Stock availability all the year around
5. Flexible payment

We accept both small orders and mass production

Company Introduction

Beijing Mesochem Technology Co., Ltd. is founded in 2009 as an independent high-tech enterprises specializing in Pharmaceutical chemicals and fine chemicals, it aims to to adapt to the business development of Beijing Huafeng United Technology Co., Ltd established in 2005.
The company locates in "Pharm Valley"'- Beijing Economic and Technological Development Zone(BDA), devotes to active pharmaceutical ingredient, intermediates and Pharmaceutical technology development services. It has independent R&D ability and right of import-export operations and has already established stable cooperation relationship with hundreds of pharmaceutical companies and research institutions both at home and abroad.
Beijing Mesochem Technology Co., Ltd has two production base at Xingan (Jiangxi Province) and Xiangyang (Hubei province), with production area about 67000 m2 and various of manufacturing equipment amount to 30000L, it has the ability of R&D, pilot production and commercial production. 80% of the products are exported to Europe, North America, South America, India and Pakistan, Southeast Asia and so on.

1. Superior quality 
2.Competitive price 
3. Good service 
4. Stock availability all the year around
5. Flexible payment

Introduction

Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac(Toradol) is used in the United States. However, unlike ketorolac, parecoxib has no effect on platelet function and therefore does not promote bleeding during or after surgery. In addition, ketorolac has a much higher gastrointestinal toxicity profile compared to most other nonsteroidal antiinflammatory drugs (NSAIDs) including ibuprofen and naprosyn. However, in the United States ketorolac is the only injectable NSAID, although it is banned in many European countries due to concerns about surgical bleeding and stomach ulcers after surgery.

All antiiflammatory medications in the U.S. carry the same warning regarding skin reactions, and none are approved for use during CABG surgery, so the reason for the FDA denying the approval of parecoxib remains unknown, but was likely related to political pressure from the US Congress to not approve another COX-2 selective inhibitor in the wake of the Vioxx affair. No COX-2 selective inhibitor has been approved in the US since that time, regardless of the safety profile of parecoxib in Europe. Efforts to try and find out the scientific rationale, or more likely the lack thereof, that the FDA used to justify the non-approval of parecoxib in the USA have proven futile due to secrecy issues.